AAPS PharmSciTech

, Volume 19, Issue 5, pp 2255–2263 | Cite as

Improving the Stability and the Pharmaceutical Properties of Norfloxacin Form C Through Binary Complexes with β-Cyclodextrin

  • Claudia GarneroEmail author
  • Ana Karina Chattah
  • Carolina Aloisio
  • Luis Fabietti
  • Marcela Longhi
Research Article


Norfloxacin, an antibiotic that exists in different solid forms, has very unfavorable properties in terms of solubility and stability. Binary complexes of norfloxacin, in the solid form C, and β-cyclodextrin were procured by the kneading method and physical mixture. Their effect on the solubility, the dissolution rate, and the chemical and physical stability of norfloxacin was evaluated. To perform stability studies, the solid samples were stored under accelerated storage conditions, for a period of 6 months. Physical stability was monitored through powder X-ray diffraction, high-resolution 13C solid-state nuclear magnetic resonance, and scanning electron microscopy. The results showed evidence that the kneaded complex increased and modulated the dissolution rate of norfloxacin C. Furthermore, it was demonstrated that the photochemical stability was increased in the complex, without affecting its physical stability. The results point to the conclusion that the new kneading complex of norfloxacin constitutes an alternative tool to formulate a potential oral drug delivery system with improve oral bioavailability.


norfloxacin C β-cyclodextrin dissolution chemical stability physical stability 



The authors wish to acknowledge the assistance of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and the Universidad Nacional de Córdoba, both of which provided support and facilities for this investigation. Also, the research group thanks the Secretaría de Ciencia y Técnica de la Universidad Nacional de Córdoba (SECyT-UNC) and Fondo para la Investigación Científica y Tecnológica (FONCYT) for financial support.

Supplementary material

12249_2018_1033_MOESM1_ESM.docx (259 kb)
ESM 1 (DOCX 258 kb)


  1. 1.
    K.D. Tripathi, Essentials of medical pharmacology, 4thEd, Jaypee Brothers, New Delhi, 1999.Google Scholar
  2. 2.
    Mazuel C. Norfloxacin. In: Florey K, editor. Analytical profiles of drug substances, vol. 20. San Diego: Academic Press; 1991. p. 557–600.CrossRefGoogle Scholar
  3. 3.
    Swanson B, Boppana V, Vlasses P, Rotmensch HH, Ferguson RK. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother. 1983;23:284–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ross DL, Riley CM. Aqueous solubilities of some variously substituted quinolone antimicrobials. Int J Pharm. 1990;63:237–50.CrossRefGoogle Scholar
  5. 5.
    Takács-Novák K, Józan M, Hermecz I, Szász G. Lipophilicity of antibacterial fluoroquinolones. Int J Pharm. 1992;79:89–96.CrossRefGoogle Scholar
  6. 6.
    Yu X, Zipp G, Davidson GWR. The effect of temperature and pH on the solubility of quinolone compounds: estimation of heat of fusion. Pharm Res. 1994;11:522–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Rusu A, Tóth G, Szacs L, Kokosi J, Kraszni M, Gyéresi Á, et al. Triprotic site-specific acid–base equilibria and related properties of fluoroquinolone antibacterials. J Pharm Biomed Anal. 2012;66:50–7. Scholar
  8. 8.
    Barbas R, Martí F, Prohens R, Puigjaner C. Polymorphism of norfloxacin: evidence of the enantiotropic relationship between polymorphs a and B. Cryst Growth Des. 2006;6:1463–7. Scholar
  9. 9.
    Puigjaner C, Barbas R, Portell A, Font-Bardia M, Alcobé X, Prohens R. Revisiting of the solid state of norfloxacin. Cryst Growth Des. 2010;10:2948–53. Scholar
  10. 10.
    Barbas R, Prohens R, Puigjaner C. A new polymorph of norfloxacin. J Therm Anal Cal. 2007;89:687–92. Scholar
  11. 11.
    Dua K, Ramana MV, Singh Sara UV, Himaja M, Agrawal A, Garg V, et al. Investigation of enhancement of solubility of norfloxacin β-cyclodextrin in presence of acidic solubilizing additives. Curr Drug Deliv. 2007;4:21–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Mendes C, Buttchevitz A, Barison A, Marins Ocampos FM, Bernardi LS, Oliveira PR, et al. Investigation of β-cyclodextrin–norfloxacin inclusion complexes. Part 2. Inclusion mode and stability studies. Expert Rev Anti-Infect Ther. 2015;13:131–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Kit Loh GO, Fung Tan YT, Khiang Peh K. Enhancement of norfloxacin solubility via inclusion complexation with β-cyclodextrin and its derivative hydroxypropyl-β-cyclodextrin. Asian J Pharm Sci. 2016;11:536–46. Scholar
  14. 14.
    Chierentin L, Garnero C, Chattah AK, Delvadia P, Karnes T, Longhi MR, et al. Influence of β-cyclodextrin on the properties of Norfloxacin form A, AAPS. Pharm Sci Tech. 2015;16:683–91. Scholar
  15. 15.
    Chattah AK, Mroue K, Pfund L, Ramamoorthy A, Longhi MR, Garnero C. Insights into novel supramolecular complexes of two solid forms of Norfloxacin and βCyclodextrin. J Pharm Sci. 2013;102:3717–24. Scholar
  16. 16.
    Nangia A, Frederick L, Cheung TH. A stability study of aqueous solution of norfloxacin. Drug Dev Ind Pharm. 1991;17:681–94. Scholar
  17. 17.
    Córdoba-Díaz M, Córdoba-Borrego M, Córdoba-Díaz D. The effect of photodegradation on the fluorescent properties of norfloxacin (Photodegradation and fluorescence of norfloxacin). J. Pharm. Biomed.l Anal. 1998;18:865–70.CrossRefGoogle Scholar
  18. 18.
    Chierentin L, Salgado H. Review of properties and analytical methods for the determination of Norfloxacin. Crit Rev Anal Chem. 2016;46:22–39. Scholar
  19. 19.
    Higuchi T, Connors KA. Phase-solubility techniques in Advances in Analytical Chemistry and Instrumentation (Vol. 4). New York: Interscience; 1965. p. 117–212.Google Scholar
  20. 20.
    The United States Pharmacopoeia (USP-35/NF-30). United States Pharmacopeial Convention Inc. In: Rockville; 2012.Google Scholar
  21. 21.
    Moore WJ, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20:64–74.Google Scholar
  22. 22.
    Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm. 2001;220:77–83.CrossRefPubMedGoogle Scholar
  23. 23.
    ICH Q1A(R2), Stability Testing of new Drug Substances and Products, 2003.Google Scholar
  24. 24.
    ICH Q2(R1), Validation of analytical procedures: text and methodology, 2005.Google Scholar
  25. 25.
    Nangia A, Frederick L, Cheung TH. A stability study of aqueous solution of norfloxacin. Drug Dev Ind Pharm. 1991;17(5):681–94.CrossRefGoogle Scholar
  26. 26.
    Harris RK. Nuclear magnetic resonance spectroscopy. London: Logman Scientific and Technical; 1994.Google Scholar
  27. 27.
    Kirchmeyer W, Grassmann O, Wyttenbach N, Alsenz J, Kuentz M. Miniaturized X-ray powder diffraction assay (MixRay) for quantitative kinetic analysis of solvent-mediated phase transformations in pharmaceutics. J Pharm Biomed Anal. 2016;131:195–201.CrossRefPubMedGoogle Scholar
  28. 28.
    Du Y, Zhang H, Xue J, Tang W, Fang H, Zhang Q, et al. Vibrational spectroscopic study of polymorphism and polymorphic transformation of the anti-viral drug lamivudine. Spectrochim Acta Part A: Molec Biomolec Spectrosc. 2015;137:1158–63.CrossRefGoogle Scholar
  29. 29.
    Paradowska K, Wawer I. Solid-state NMR in the analysis of drugs and naturally occurring materials. J Pharm Biomed Anal. 2014;93:27–42.CrossRefPubMedGoogle Scholar
  30. 30.
    Zoppi A, Garnero C, Garro Linck Y, Chattah AK, Monti G, Longhi MR. Enalapril:β-CD complex: stability enhancement in solid state. CarbohydPolym. 2011;86:716–21. Scholar
  31. 31.
    Monti GA, Chattah AK, Garro Linck Y. Solid-state nuclear magnetic resonance in pharmaceutical compounds. Annual Reports on NMR Spectroscopy. 2014;83:221–69.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Claudia Garnero
    • 1
    • 2
    Email author
  • Ana Karina Chattah
    • 3
  • Carolina Aloisio
    • 1
    • 2
  • Luis Fabietti
    • 3
  • Marcela Longhi
    • 1
    • 2
  1. 1.Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de CórdobaCiudad UniversitariaCórdobaArgentina
  2. 2.Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA) CONICET-UNCCiudad UniversitariaCórdobaArgentina
  3. 3.Facultad de Matemática, Astronomía, Física y Computación, Universidad Nacional de Córdoba and IFEG (CONICET)CórdobaArgentina

Personalised recommendations